Andreas Migdanis
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition that significantly impacts patients' quality of life. Biologic therapies have revolutionized the management of IBD by targeting specific components of the immune system. This review provides an overview of the latest advances in biologic therapies for IBD, focusing on their efficacy and safety profiles. Recent biologics, including anti-TNF agents, integrin inhibitors and IL-12/23 inhibitors, have shown substantial efficacy in inducing and maintaining remission in IBD patients. However, their use is associated with potential risks, including infections and malignancies. Understanding the benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 